Celldex Therapeutics Inc (CLDX)

NASD · Healthcare · Biotechnology · USA

Celldex Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibodies targeting mast cell biology to treat inflammatory, allergic, and autoimmune diseases. The company's primary program, barzolvolimab, is being studied in chronic spontaneous urticaria, cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis. Its pipeline also includes CDX-622, a bispecific antibody candidate for inflammatory diseases.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Celldex Therapeutics Inc stock.

Our verdict on CLDX

Overvalued: intrinsic value $6.10 per share, market price $28.04, margin of safety -359.9% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $6.10; the price of $28.04 is 360% above that value.

ETFs with the most weight in CLDX

17 more funds hold it; the full list is part of the paid plan.

More on CLDX

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than CLDX in Biotechnology

81 more in this industry show a wider margin of safety.

Is CLDX undervalued or overvalued?

CLDX is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.10; the price of $28.04 is 360% above that value.

What is the intrinsic value of CLDX?

$6.10 per share (as of the 2026-11-17 close), against a market price of $28.04. That is a margin of safety of -359.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.